Pain Therapeutics (NASDAQ:PTIE) shares dropped 3.8% on Tuesday . The stock traded as low as $2.49 and last traded at $2.51, with a volume of 77,022 shares traded. The stock had previously closed at $2.61.

Separately, Zacks Investment Research upgraded shares of Pain Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 31st.

The firm’s 50-day moving average price is $2.35 and its 200-day moving average price is $2.17. The company’s market cap is $115.81 million.

Pain Therapeutics (NASDAQ:PTIE) last issued its quarterly earnings data on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.07. On average, equities analysts anticipate that Pain Therapeutics will post ($0.42) EPS for the current year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.